Dopamine: Difference between revisions
imported>Robert Badgett (New article) |
imported>Robert Badgett (Started 'Clinical pharmacology') |
||
| Line 20: | Line 20: | ||
Agonists of D3, especially nonergot agonists such as pramipexole and ropinirole, may be used to treat [[Parkinonism]] and restless legs syndrome.<ref name="pmid18474889">{{cite journal |author=Baker WL, White CM, Coleman CI |title=Effect of nonergot dopamine agonists on symptoms of restless legs syndrome |journal=Ann Fam Med |volume=6 |issue=3 |pages=253–62 |year=2008 |pmid=18474889 |doi=10.1370/afm.845 |url=http://www.annfammed.org/cgi/pmidlookup?view=long&pmid=18474889 |issn=}}</ref> | Agonists of D3, especially nonergot agonists such as pramipexole and ropinirole, may be used to treat [[Parkinonism]] and restless legs syndrome.<ref name="pmid18474889">{{cite journal |author=Baker WL, White CM, Coleman CI |title=Effect of nonergot dopamine agonists on symptoms of restless legs syndrome |journal=Ann Fam Med |volume=6 |issue=3 |pages=253–62 |year=2008 |pmid=18474889 |doi=10.1370/afm.845 |url=http://www.annfammed.org/cgi/pmidlookup?view=long&pmid=18474889 |issn=}}</ref> | ||
;D4 receptors | ;D4 receptors | ||
==Clinical pharmacology== | |||
===Dopamine agonists=== | |||
Dopamine agonists are "dugs that bind to and activate dopamine receptors."<ref name="MeSH-DopamineAgonists">{{MeSH|Dopamine agonists}}</ref> | |||
===Dopamine antagonists=== | |||
Dopamine antagonists are "drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders ([[antipsychotic agent]]s) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as [[antiemetic]]s, in the treatment of [[Tourette syndrome]], and for [[hiccup]]. Dopamine receptor blockade is associated with [[neuroleptic malignant syndrome]]."<ref name="MeSH-DopamineAntagonists">{{MeSH|Dopamine antagonists}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 06:40, 9 September 2009
Dopamine is "one of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (dopamine receptors) mediate its action."[1]
Dopamine regulates the secretion of prolactin from the anterior pituitary gland. Dopamine is released from specialised neurons of the arcuate nucleus of the hypothalamus into the blood vessels of the median eminence, which transport the dopamine to the pituitary gland where it inhibits prolactin secretion from lactotroph cells.
Dopamine receptors
D1-like receptors
These receptors stimulate adenylate cyclase.[2]
- D1 receptors
- D5 receptors
D2-like receptors
These receptors inhibit adenylate cyclase.[3]
- Dopamine D2 receptors
Agonists, such as metoclopramide, are used as antiemetics.
Antagonists, such as risperidone and haloperidol, are used to treat schizophrenia.[4]
Blockade of the D2 receptors, which may be predisposed by genetic polymorphisms of the allele, may cause neuroleptic malignant syndrome.[5]
- D3 receptors
Agonists of D3, especially nonergot agonists such as pramipexole and ropinirole, may be used to treat Parkinonism and restless legs syndrome.[6]
- D4 receptors
Clinical pharmacology
Dopamine agonists
Dopamine agonists are "dugs that bind to and activate dopamine receptors."[7]
Dopamine antagonists
Dopamine antagonists are "drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with neuroleptic malignant syndrome."[8]
References
- ↑ Anonymous (2024), Dopamine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Receptors, Dopamine D1 (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Receptors, Dopamine D2 (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Katzung, Bertram G. (2001). Basic & clinical pharmacology. New York: Lange Medical Books/McGraw-Hill, 483. ISBN 0-8385-0598-8.
- ↑ Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004). "Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene". Mol. Psychiatry 9 (3): 293-8. DOI:10.1038/sj.mp.4001422. PMID 15094790. Research Blogging.
- ↑ Baker WL, White CM, Coleman CI (2008). "Effect of nonergot dopamine agonists on symptoms of restless legs syndrome". Ann Fam Med 6 (3): 253–62. DOI:10.1370/afm.845. PMID 18474889. Research Blogging.
- ↑ Anonymous (2024), Dopamine agonists (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Dopamine antagonists (English). Medical Subject Headings. U.S. National Library of Medicine.